Funding Rounds
Artcline

Artcline Series A (2024, $4M)

Artcline

Immune cell-based extracorporeal sepsis therapy developer.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series A

Raised Amount: $4.77M